DBV Technologies expands its scientific advisory board
This article was originally published in Scrip
Executive Summary
DBV Technologies (France), a biopharmaceutical company focused on the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, has expanded its scientific advisory board with the appointments of Professor Gideon Lack and Associate Professor Philippe Eigenmann. Professor Lack is head of the children’s allergy service at Guy's and St Thomas' NHS Foundation Trust and a professor of paediatric allergy at King's College, London, while Professor Eigenmann is an associate professor at the department of infants and adolescents at the Hospital cantonal Universitaire Genève, Switzerland, specialising in paediatric allergy diagnosis and treatment.